Advertisement
JNJ or PFE or PRAX
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Pfizer (PFE) vs. Praxis Precision Medicines (PRAX) Stock Comparison
Key Takeaways
- JNJ exhibits strong year-to-date gains around 16%, driven by a diversified portfolio in innovative medicine and MedTech, with recent approvals bolstering sentiment.
- PFE shows moderate YTD performance near 11%, supported by oncology focus amid mixed vaccine trial results, offering higher dividend yield but facing post-COVID challenges.
- PRAX, a clinical-stage biotech, delivers explosive 1-year returns over 700% but higher volatility, fueled by NDA filings for CNS therapies like ulixacaltamide and relutrigine.
- JNJ leads in market cap (~$567B) and revenue stability ($94B TTM), contrasting PRAX's pre-revenue status and growth potential versus PFE's $153B cap and $63B revenue.
- Recent momentum favors PRAX with Phase 3 advancements, while JNJ and PFE provide defensive stability in healthcare amid market volatility.
- Valuation metrics highlight JNJ's P/E ~21x, PFE ~20x, with PRAX unprofitable but trading on pipeline catalysts.
Introduction
This stock comparison examines JNJ, PFE, and PRAX in the healthcare sector, spanning established giants and emerging biotech. Johnson & Johnson and Pfizer represent blue-chip stability with broad portfolios in pharmaceuticals and MedTech, while Praxis Precision Medicines focuses on precision therapies for CNS disorders. Traders seeking relative performance insights and investors eyeing growth versus defense will find value here, particularly amid recent regulatory milestones and market shifts influencing sentiment and positioning.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) is a global healthcare leader in Innovative Medicine—covering oncology, immunology, neuroscience—and MedTech for orthopedics, surgery, and vision. With ~138,000 employees and $94B in trailing twelve-month revenue, it maintains robust profitability.
In recent market activity, JNJ has traded around $235-$240, posting YTD returns of ~16% outperforming the S&P 500's 4%. Weekly pullbacks of ~1-4% reflect broader volatility, but approvals for psoriasis treatments and blood cancer therapies have supported sentiment. Strong Q4 revenue growth (~6% YoY) and EBITDA surge (~71%) underscore operational resilience, with P/E ~21x signaling steady valuation.
PFE Overview and Recent Performance
Pfizer (PFE) is a biopharma powerhouse discovering therapies in oncology, vaccines, internal medicine, and rare diseases, with ~75,000 employees and $63B in 2025 revenues. Key products include Prevnar vaccines and Eliquis for cardiovascular care.
Recent weeks saw PFE fluctuate ~$26-$28, with YTD gains ~11% and 1-year ~14%. A Lyme vaccine trial missing primary but hitting secondary endpoints (~70% efficacy) mixed sentiment, alongside breast cancer progress. Monthly dips (~1%) contrast oncology momentum, with P/E ~20x and high dividend (~6%) attracting yield seekers amid post-COVID adjustments.
PRAX Overview and Recent Performance
Praxis Precision Medicines (PRAX) is a clinical-stage biotech leveraging genetic epilepsy insights via Cerebrum (small molecules) and Solidus (ASOs) platforms for CNS disorders like essential tremor and epileptic encephalopathies. With 168 employees, it remains pre-revenue, focusing on NDAs for ulixacaltamide and relutrigine.
PRAX has surged, trading ~$290-$350 recently, with 1-year returns >700% and YTD ~4%. Volatility shows monthly declines (~10-12%), but FDA NDAs and Phase 3 trials drive momentum, contrasting profitability peers. High beta (~3x) reflects biotech risks tied to catalysts.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 AI-powered trading bots from over 351 available, optimized for current market conditions like volatility in energy, semiconductors, and healthcare. These bots, including Signal, Virtual, and Brokerage Agents, deliver annualized returns from 15% to 138%, win rates up to 89%, and profit factors to 12x, with strategies spanning trend-following, swing trading, hedging via 2x/3x ETFs, and multi-agent AI on timeframes like 5-60 minutes. Trading 8-25 tickers across sectors—such as oil (XOM, CVX), semis (SOXL, LRCX), and defense (LMT)—they emphasize risk management with 2-3% take-profits and drawdowns under $50K. Explore these high performers to align with your strategy.
Head-to-Head Comparison
JNJ and PFE offer stable business models with diversified revenues—JNJ blending pharma/MedTech, PFE emphasizing vaccines/oncology—versus PRAX's focused CNS pipeline. Growth drivers differ: PRAX rides NDA catalysts for 700%+ 1-year gains, while JNJ (~16% YTD) and PFE (~11%) prioritize steady expansion amid litigation risks for both giants.
Recent momentum favors PRAX's volatility (beta 3x), contrasting JNJ/PFE's defense. Risks include PRAX's trial failures/no revenue, PFE's patent cliffs, and JNJ's talc suits. Sector exposure skews broad healthcare for majors, neurology for PRAX. Valuations show JNJ P/E 21x, PFE 20x (high yield), PRAX speculative on milestones; sentiment tilts toward JNJ's consistency.
Tickeron AI Verdict
Tickeron’s AI currently leans toward JNJ for its trend consistency, ~16% YTD outperformance, pipeline approvals, and balanced risk in volatile markets. PRAX offers higher-upside potential via catalysts but elevated volatility, while PFE suits income focus. Observable stability and relative positioning favor JNJ probabilistically in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 0 green FA rating(s), and PRAX’s FA Score reflects 0 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 0 green, 5 red.
- PRAX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s), and PRAX’s TA Score reflects 5 bullish TA indicator(s).
- JNJ’s TA Score: 3 bullish, 6 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
- PRAX’s TA Score: 5 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -1.79% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.38% , and PRAX (@Biotechnology) price fluctuated +8.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
JNJ is expected to report earnings on Jul 22, 2026.
PFE is expected to report earnings on May 05, 2026.
PRAX is expected to report earnings on May 13, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| JNJ | PFE | PRAX | |
| Capitalization | 564B | 157B | 9.54B |
| EBITDA | 41.1B | 16.8B | -326.06M |
| Gain YTD | 13.759 | 12.537 | 16.204 |
| P/E Ratio | 21.23 | 20.26 | N/A |
| Revenue | 94.2B | 62.6B | 0 |
| Total Cash | 20.1B | 13.6B | 599M |
| Total Debt | 47.9B | 64B | 110K |
JNJ | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 11 | 100 | |
SMR RATING 1..100 | 27 | 74 | |
PRICE GROWTH RATING 1..100 | 45 | 48 | |
P/E GROWTH RATING 1..100 | 41 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (26) in the Pharmaceuticals Major industry is in the same range as PFE (34). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
JNJ's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that JNJ’s stock grew significantly faster than PFE’s over the last 12 months.
JNJ's SMR Rating (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (74). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as PFE (48). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as JNJ (41). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | PFE | PRAX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 42% | 2 days ago 66% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 52% | 2 days ago 51% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 32% | 2 days ago 55% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 40% | 2 days ago 55% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 51% | 2 days ago 88% |
| Advances ODDS (%) | 10 days ago 44% | 2 days ago 56% | 5 days ago 84% |
| Declines ODDS (%) | 2 days ago 41% | 9 days ago 57% | 3 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 48% | 2 days ago 52% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 38% | 2 days ago 52% | 2 days ago 86% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XOVR | 18.36 | 0.30 | +1.66% |
| ERShares Private-Public Crossover ETF | |||
| IVV | 713.36 | 8.62 | +1.22% |
| iShares Core S&P 500 ETF | |||
| XEMD | 45.04 | 0.31 | +0.69% |
| BondBloxx JP Morgan USD EM 1-10 Yr BdETF | |||
| IG | 20.82 | 0.08 | +0.40% |
| Principal Investment Grd Corp Actv ETF | |||
| AMZP | 27.87 | 0.10 | +0.36% |
| Kurv Yield Premium Str Amazon ETF | |||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.25% | ||
| MRK - PFE | 66% Loosely correlated | +3.13% | ||
| BMY - PFE | 64% Loosely correlated | +2.05% | ||
| BIIB - PFE | 61% Loosely correlated | +0.76% | ||
| AMGN - PFE | 58% Loosely correlated | +1.69% | ||
| NVS - PFE | 54% Loosely correlated | +1.50% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | +6.90% | ||
| BEAM - PRAX | 40% Loosely correlated | +3.49% | ||
| BHVN - PRAX | 37% Loosely correlated | +9.69% | ||
| RAPP - PRAX | 35% Loosely correlated | +0.58% | ||
| VERU - PRAX | 35% Loosely correlated | -1.21% | ||
| RXRX - PRAX | 35% Loosely correlated | +5.00% | ||
More | ||||